BPC-157 + TB-500 is a dual-peptide research blend combining Body Protection Compound 157 (BPC-157) and Thymosin Beta-4 (TB-500), two peptides commonly studied in laboratory environments for their potential role in cellular repair processes, tissue remodelling, and extracellular matrix signalling pathways
None of the three GLOW compounds are FDA-approved for injectable human use as of June 2026
Importantly, it remains unclear whether the disease process itself may contribute to elevated vitamin B12 levels
Hierarchy does not apply to subcutaneous/intramuscular injections
Vitamin C can also help with inflammation in the body, fighting off infections, fatigue, depression, and overactive thyroid issues
For a direct comparison with the parallel peptide under review, see our TB-500 FDA approval status 2026 article